https://i1.wp.com/genderpolicyreport.umn.edu/wp-content/uploads/2017/03/1427632177_7c26428e50_z.jpg?fit=640%2C426 426 640 Debra Fitzpatrick http://genderpolicyreport.umn.edu/wp-content/uploads/2016/12/gendereport.png Debra Fitzpatrick2017-03-14 13:57:482017-03-14 13:57:48Safety Implications of Regulatory Rollback at the FDA
Prescription drugs in recent years have experienced breathtaking price hikes and occasionally have proven dangerous after they have gone on the market. What is happening with these issues since the Trump administration took office? For one, President Trump announced recently his intention to roll back FDA regulations as much as 75%. Scott Gottlieb has just been named Trump’s choice to lead the FDA, and he as well as the other two candidates, Jim O’Neill and Joseph Gulfo, called for streamlining regulatory procedures. Jim O’Neill even called for drugs to be tested only for safety. Once marketed, individuals can take new drugs “at their own risk” and thereby prove – or disprove – their effectiveness.